Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Using a contaminated solution can invalidate your research and is a significant safety concern
Table 9: Results at Week 52 in a Trial Comparing TRESIBA to Insulin Glargine U-100 in Adult Patients with Type 2 Diabetes Mellitus on OAD(s)* *OAD: oral antidiabetic agent **The change from baseline to end of treatment visit in HbA1c was analyzed using ANOVA with treatment, region, sex, and anti-diabetic treatment at screening as fixed effects, and age and baseline HbA1c as covariates
Archived from the original on 5 February 2022
Genetic Predispositions and Personalized Risk Assessment Emerging evidence suggests that variants in FTO (rs9939609) genes may correlate with individual differences in GLP-1 side-effect severity and tolerability profiles
Thorne, A.I
-, ,
US$ 29.11
US$ 24.09
US$ 23.08
US$ 26.41
US$ 29.80
